BU
BIO icon

BBVA USA’s Bio-Rad Laboratories Class A BIO Stock Holding History

BBVA USA’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$2.5M Sell
3,352
-265
-7% -$199K 0.15% 146
2021
Q2 		$2.33M Buy
+3,617
New +$2.2M 0.13% 155

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BBVA USA's BIO Position: Q3 2021 in Review

BBVA USA reduced its Bio-Rad Laboratories Class A (BIO) stake by 7.3% in Q3 2021, selling an estimated $199K and leaving 3,352 shares worth $2.5M. The position accounts for 0.15% of the portfolio, ranked #146.

BBVA USA first reported a position in BIO in Q2 2021 and has held it in 2 quarters since. 507 funds tracked by Wall St. Rank hold BIO as of Q3 2021.

  • BBVA USA held 3,352 shares of Bio-Rad Laboratories Class A worth $2.5M as of Q3 2021.
  • BBVA USA sold 265 Bio-Rad Laboratories Class A shares in Q3 2021, an estimated $199K.
  • Bio-Rad Laboratories Class A made up 0.15% of BBVA USA's portfolio in Q3 2021, its #146 holding.
  • BBVA USA first reported a position in Bio-Rad Laboratories Class A in Q2 2021 and has held it in 2 quarters since.
  • 507 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.